• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

The objective of this scientific statement is to evaluate contemporary evidence that either
supports or refutes the conclusion that aggressive low-density lipoprotein cholesterol …

The diagnosis of peripheral arterial disease (PAD) is not always evident as symptoms and
signs may show great variation. As all grades of PAD are linked to both an increased risk for …

Low-density lipoprotein (LDL) indubitably contributes causally to atherosclerosis, a leading
challenge to health worldwide. Interventions that lower LDL cholesterol (LDL-C) have made …

Panvascular diseases refer to a series of vascular diseases with atherosclerosis as the
common pathological feature, mainly affecting important organs such as the heart, brain …

Depressed low-density lipoprotein (LDL) cholesterol concentration protects against
atherosclerotic cardiovascular disease. Natural hypocholesterolemia states can have a …

Atherosclerosis is a multifactorial, lipoprotein-driven condition that leads to plaque formation
within the arterial tree, leading to subsequent arterial stenosis and thrombosis that accounts …

PCSK9i represent a potent class of lipid-lowering therapies that are well tolerated and
effective in a wide group of patients with high-risk atherosclerotic cardiovascular disease …

The past year was an exciting time for clinical lipidology when we learnt more about existing
therapies as well as therapies targeting novel pathways discovered through genetic studies …

Abstract Purpose of Review We reviewed lipid-modifying therapies and the risk of stroke and
other cerebrovascular outcomes, with a focus on newer therapies. Recent Findings Statins …